Multiple groups have demonstrated that local oncolytic virus injection can modulate tumor-specific CD8+ T-cell responses to make distant tumors increasingly susceptible to immune checkpoint inhibitor therapy [100, 105]. The gene discussed is CD8A; the disease is neoplasm.